Urinary Cytokine Levels as a Prognostic Marker for Kidney Scarring After Pyelonephritis

This study is not yet open for participant recruitment.

Verified by Hillel Yaffe Medical Center, March 2009

First Received: March 22, 2009 No Changes Posted

Sponsored by:	Hillel Yaffe Medical Center
Information provided by:	Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:	NCT00868270

Purpose

The prevalence of kidney scarring after UTI is approximately 5-57%. UTIs are caused mainly by bacteria that cause local and systemic immunological reaction that are accompanied by cytokines. These cytokines are a main factor in the inflammatory process. They are produced by leukocytes, macrophages, fibroblasts, endothelial cells and epithelial cells in the kidney tissue. Interleukin 6 and 8 (IL-6 IL-8) were found in high levels in the urine of children and adults who suffer from UTIs. Other studies on animals have found a relationship between inflammatory reaction and scarring in the kidney. We hypothesize that we will find a similar relationship between the level of IL-6, IL-8 in the urine during acute pyelonephritis in children and the probability of kidney scarring.

Condition
Kidney Scarring Post-Febrile UTI

MedlinePlus related topics: Scars Urine and Urination

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective

Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:

High prevalence of kidney scarring in children with high levels of urine interleukins [ Time Frame: six months ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	35
Study Start Date:	May 2009

Groups/Cohorts
Children with UTIs

Eligibility

Ages Eligible for Study:	up to 7 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Hospitalized children with UTIs

Criteria

Inclusion Criteria:

Children aged 0-7
First episode febrile UTI

Exclusion Criteria:

Recurrent UTI

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00868270

Contacts

Contact: Hassan Jassar, MD

972-4-630-4332

hasjassar@hotmail.com

Locations

Israel
Hillel Yaffe Medical Center
Hadera, Israel, 38100

Sponsors and Collaborators

Hillel Yaffe Medical Center

More Information

No publications provided

Responsible Party:	Pediatrics Dept. Hillel Yaffe Medical Center ( Hassan Jassar, MD )
Study ID Numbers:	HY55-08
Study First Received:	March 22, 2009
Last Updated:	March 22, 2009
ClinicalTrials.gov Identifier:	NCT00868270 History of Changes
Health Authority:	Israel: Ministry of Health

Study placed in the following topic categories:

Fever
Skin Diseases
Pyelonephritis
Cicatrix

Additional relevant MeSH terms:

Skin Diseases
Cicatrix

ClinicalTrials.gov processed this record on May 07, 2009